Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Vaccines

Free Subscription 06.04.2026 1 BMJ 1 Indian Pediatr 1 Infect Immun 2 J Infect Dis 1 J Virol 1 MMWR Morb Mortal Wkly Rep 1 Nat Immunol 2 PLoS Comput Biol 6 PLoS One 22 Vaccine 2 Virology 2 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMJ

1. WISE J
   RSV vaccination programme expanded to 3 million more older people.
   BMJ. 2026;393:s646.
   PubMed        
   
   

   
   Indian Pediatr

2. MOHAN N
   HPV Vaccination: A Transformative Step Towards Eliminating Cervical Cancer in India.
   Indian Pediatr. 2026 Mar 31. doi: 10.1007/s13312-026-00326.
   PubMed        
   
   

   
   Infect Immun

3. THAYER TC, Cox A, Gonzalez E, Mangiafesto J, et al
   Lipidated Protein D vaccination elicits humoral and cellular responses and protects mice against challenge with non-typeable Haemophilus influenzae.
   Infect Immun. 2026 Mar 31:e0064725. doi: 10.1128/iai.00647.
   PubMed         Abstract available
   
   

   
   J Infect Dis

4. LUTZ CS, Filardo TD, DeJonge PM, Gretsch S, et al
   Effectiveness of Measles-Mumps-Rubella Vaccination Among Persons Residing in a Congregate Migrant Shelter During a Measles Outbreak: An Observational Cohort Study.
   J Infect Dis. 2026 Apr 1:jiaf650. doi: 10.1093.
   PubMed         Abstract available
   
   
5. HUNT JH, Damhorst GL, Parsons R, Frediani JK, et al
   Peak Nasal SARS-CoV-2 and Influenza Viral Loads Relative to Symptom Onset, 2022-2025: Impact of Vaccination and Implications for Multiplexed Testing.
   J Infect Dis. 2026 Apr 1:jiag169. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

6. KIM K-H, Hwang HS, Pal SS, Tien Le CT, et al
   Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunity.
   J Virol. 2026 Mar 27:e0022926. doi: 10.1128/jvi.00229.
   PubMed         Abstract available
   
   

   
   MMWR Morb Mortal Wkly Rep

7. MEGHANI M, Garacci Z, Razzaghi H, de Perio MA, et al
   Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2024-25 Respiratory Virus Season.
   MMWR Morb Mortal Wkly Rep. 2026;75:164-171.
   PubMed         Abstract available
   
   

   
   Nat Immunol

8. CHAULAGAIN S, Liu JA, McCombs JE, Klein SL, et al
   Sex differences in immune responses to viruses, bacteria and vaccines.
   Nat Immunol. 2026;27:660-673.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

9. NIGHTINGALE ES, Pham-Minh L, Bello IM, Okrior S, et al
   Sub-national modelling of surveillance sensitivity to inform declaration of disease elimination: A retrospective validation against the elimination of wild poliovirus in Nigeria.
   PLoS Comput Biol. 2026;22:e1013984.
   PubMed         Abstract available
   
   
10. ORSINELLI-RIVERS S, Beaglehole D, Einav T
    CAPYBARA: A generalizable framework for predicting serological measurements across human cohorts.
    PLoS Comput Biol. 2026;22:e1014129.
    PubMed         Abstract available
    
    

    
    PLoS One

11. BRAUN J, Hill ED, Contreras E, Yasuda M, et al
    Contrasting effects of SARS-CoV-2 vaccination vs. infection on antibody and TCR repertoires.
    PLoS One. 2026;21:e0343939.
    PubMed         Abstract available
    
    
12. CHANG T, Deng C, Xie L, Zheng Y, et al
    Stirred tank bioreactor process for chikungunya vaccine candidate VEEV-DeltaC-CHIKV.
    PLoS One. 2026;21:e0344564.
    PubMed         Abstract available
    
    
13. AWAD R, Rahal M, Henieneh AM, Salameh P, et al
    Social determinants of vaccine hesitancy among the Lebanese parents: A cross-sectional Study.
    PLoS One. 2026;21:e0345153.
    PubMed         Abstract available
    
    
14. OBENG MA, Okwan DK, Boateng CO, Scott GY, et al
    Towards hepatitis B elimination in Ghana: vaccination coverage and its predictors among informal sector workers in Kejetia, Kumasi, Ghana.
    PLoS One. 2026;21:e0334205.
    PubMed         Abstract available
    
    
15. KIJERA B, Sowe A, Bobb M, Jarjusey S, et al
    Timeliness of routine vaccination among 24-35 months children in Urban Gambia.
    PLoS One. 2026;21:e0346048.
    PubMed         Abstract available
    
    
16. IUNES FM, Aranha Rossi T, Soares F, Torres TS, et al
    Factors associated with COVID-19 vaccination schedule completion among adults in high-social-vulnerability neighborhoods in two Brazilian state capitals: A cross-sectional study.
    PLoS One. 2026;21:e0346091.
    PubMed         Abstract available
    
    

    
    Vaccine

17. MAEDA H, Saito N, Igarashi A, Ishida M, et al
    Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUS.
    Vaccine. 2026;80:128544.
    PubMed         Abstract available
    
    
18. YANG S, Dai D, Kang Z, Zhang L, et al
    Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial.
    Vaccine. 2026;80:128527.
    PubMed         Abstract available
    
    
19. CALLEWAERT K, Lavreys L, Willems W, van Rosmalen MGM, et al
    Vaccine-induced seropositivity/seroreactivity (VISP/R) on common HIV screening assays after vaccination with investigational adenovirus vector-based mosaic HIV regimens in clinical trials.
    Vaccine. 2026;79:128500.
    PubMed         Abstract available
    
    
20. LUCIDARME J, Clark SA, Borrow R, Murthy AK, et al
    Ability of the MenB-fHbp vaccine to provide immune protection against meningococcal serogroup B ST-1161 UK university "South West Outbreak" strain isolates.
    Vaccine. 2026;80:128503.
    PubMed         Abstract available
    
    
21. PAN H, Zhao J, Yang J, Cao W, et al
    A ?ssaV deletion attenuates Salmonella Choleraesuis to generate a self-limiting, immunogenic vaccine candidate.
    Vaccine. 2026;80:128546.
    PubMed         Abstract available
    
    
22. CHAN CP, Wong NS, Lee SS
    Normalising enhanced influenza vaccines as a strategy to promote vaccination uptake in healthcare workers: Insights from a discrete choice experiment.
    Vaccine. 2026;80:128539.
    PubMed         Abstract available
    
    
23. WU D, Liu K
    Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.
    Vaccine. 2026;80:128536.
    PubMed         Abstract available
    
    
24. VAN DE BURGWAL LHM, Pronker ES, Herz J
    Australia's vaccine legacy: Time for a boost? Mapping an innovation system in a fragmented data environment.
    Vaccine. 2026;80:128525.
    PubMed         Abstract available
    
    
25. QU S, Zhou M, Campy KS, Bu P, et al
    An integrated health belief model and protection motivation theory approach to understanding herpes zoster vaccination intention among older adults in China.
    Vaccine. 2026;80:128508.
    PubMed         Abstract available
    
    
26. PHIJFFER EWEM, Sivakumar C, van den Hoogen A, Crombag NMTH, et al
    Preferences of Dutch pregnant women for RSV immunisation - a mixed method study.
    Vaccine. 2026;78:128409.
    PubMed         Abstract available
    
    
27. SHIGAYEVA A, Coleman BL, Golden AR, Martin I, et al
    Prevalence of and risk factors for antimicrobial resistance in pneumococcal disease in southern Ontario during the PCV13 era.
    Vaccine. 2026;78:128351.
    PubMed         Abstract available
    
    
28. SABATE M, Riera-Arnau J, Ballarin E, Pares-Badell O, et al
    Validation of Guillain-Barre syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria.
    Vaccine. 2026;78:128397.
    PubMed         Abstract available
    
    
29. TSCHERNE A, Krammer F
    Seven decades after the Asian influenza pandemic: A historical review about immunity and vaccines against H2N2.
    Vaccine. 2026;79:128467.
    PubMed         Abstract available
    
    
30. LIU Y, Wu B, Wei M, Gong R, et al
    E-health literacy and herpes zoster vaccination intention: Health belief pathways and socioeconomic inequalities.
    Vaccine. 2026;80:128502.
    PubMed         Abstract available
    
    
31. ROBERTSON AH, Wolf AS, Fossum E, Solum G, et al
    Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.
    Vaccine. 2026;80:128511.
    PubMed         Abstract available
    
    
32. PODER A, Trinidad-Aseron M, Van Twuijver E, Versage E, et al
    Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study.
    Vaccine. 2026;80:128504.
    PubMed         Abstract available
    
    
33. ALKAN C, Jurado-Cobena E, Ikegami T
    Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models.
    Vaccine. 2026;80:128526.
    PubMed         Abstract available
    
    
34. HASAN AZ, Dombola AM, Prosperi C, Mufwambi W, et al
    Assessing the effectiveness of school-based vaccination checks to identify and reach un - and under-vaccinated students in Zambia.
    Vaccine. 2026;79:128453.
    PubMed         Abstract available
    
    
35. COORAY U, Singh A, Peres MA
    Long-term impacts of HPV vaccination strategies on HPV related Cancer burden among Singaporean female population: A prospective simulation using proportional multistate lifetables.
    Vaccine. 2026;80:128513.
    PubMed         Abstract available
    
    
36. DLOUHY P, Petras M, Lesna IK, Macalik R, et al
    Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis.
    Vaccine. 2026;80:128535.
    PubMed         Abstract available
    
    
37. YITBAREK K, Sheel M, Woldie M, Mahimbo A, et al
    Spatial and temporal trends of measles and measles vaccination status in Ethiopia, 2015-2024.
    Vaccine. 2026;80:128524.
    PubMed         Abstract available
    
    
38. HOOPER ME, Jojo N, Davis D, Blackburn J, et al
    Factors influencing vaccine uptake in people from culturally and linguistically diverse communities in Australia: An integrative review.
    Vaccine. 2026;80:128528.
    PubMed         Abstract available
    
    

    
    Virology

39. LIU R, Patterson L, Yeasmin M, Kim KH, et al
    Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.
    Virology. 2026;619:110884.
    PubMed         Abstract available
    
    
40. CHUNG YJ, Oh HS, Kim SO, Hong SP, et al
    Protective efficacy of GMAI-02, a cDNA-derived inactivated hepatitis A vaccine, against HM175/mp7 challenge in interferon-receptor-deficient mice.
    Virology. 2026;619:110883.
    PubMed         Abstract available
    
    

    
    Virus Res

41. SITHOLE MN, Khan MR, Mohammed HA, Khan RA, et al
    A Systematic Review on Vaccine Developmental Approaches: Evaluating Efficacy, and Addressing Challenges of Infectious Diseases in the Post-COVID-19 Era.
    Virus Res. 2026 Apr 1:199720. doi: 10.1016/j.virusres.2026.199720.
    PubMed         Abstract available
    
    
42. YUNUS AO, Olanrewaju OA
    Fractional-order Modeling of Vaccination Strategies for Measles Transmission Incorporating Immune Memory.
    Virus Res. 2026 Mar 28:199718. doi: 10.1016/j.virusres.2026.199718.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum